Commentary

The last time the Investment Industry Regulatory Organization of Canada (IIROC) intervened in the trading of Canadian publicly traded cannabis companies was in November 2016. Canopy Growth Corp, the first, biggest, and most valuable ACMPR-licensed grower had popped to over $17 a share on no news, and IIROC halted trading to “to ensure a fair and orderly market.” IIROC halted stocks multiple times that day, with trading resuming on an average of about 10 minutes later in all cases. [...]
James West

AlphaNorth Asset Management CEO Steven Palmer sat down with James to talk about what companies the Toronto-based investment manager has invested in, including in the blockchain, AI, lithium, gold, and cannabis sectors. TRANSCRIPT: [...]
MidasLetter Live
New Cannabis Ventures and 420Investor CFA Alan Brockstein joins to talk about the emerging opportunities in the Cannabis space, and how investors need to watch out as the darker underbelly of capital markets are attracted to the rich valuations currently being experienced in certain issuers.

Within the text of Bill C-45 The Cannabis Act are sown the seeds for the program’s potential failure. The Liberal Government has limited time to change course and avoid both a price war and a flood [...]
James West

With self-congratulatory accolades flowing effusively from within America starting at the top with Donald Trump, it behooves the objective market participant to recall the reasons that have caused the Dow’s meteroic rise to [...]
James West

Cannabis Wheaton Income Corporation (CVE:CBW) (OTCMKTS:KWFLF) (FRA:3KF) is getting hammered today, as is MedReleaf on the first day of its IPO, despite having closed a $100 million financing. Cannabis Wheaton is already underwater [...]
James West

Free Newsletter,
Priceless Content.

Get more of Midas Letter delivered right to your inbox.

Special Offer

Sign-up today and receive free and immediate access to three recently published special reports!

Free Newsletter,
Priceless Content.

Get more of Midas Letter delivered right to your inbox.

Special Offer

Sign-up today and receive free and immediate access to three recently published special reports!